Shares of Moderna and other vaccine makers dropped Monday after the Food and Drug Administration's vaccine chief, Peter Marks ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of ...

Shares of Moderna (NASDAQ: MRNA) are falling on Monday. The steep decline comes as the S&P 500 and Nasdaq Composite lost 0.4% and 1.1%, respectively. The vaccine maker's shares tumbled following the ...

Moderna Inc MRNA -11.5% Get Free Report shares were down 13.5% at $26.88 and Novavax Inc NVAX -9.02% Get Free Report shares ...

Why not all African countries should venture into vaccine business ANALYSIS | The African Union has embarked on one of its ...

Preparations are underway for a limited spring COVID-19 vaccination program in Alberta. Pharmacists have been told certain ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

Food and Drug Administration Commissioner Marty Makary signed off on the ouster of top vaccine official Peter Marks shortly ...

Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...